Hashimoto M, Fukiage K, Taniguchi K, Minami T, et al. Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab. Transl Androl Urol 2025;14:2279-2288.
PMID: 40949456